ProfileGDS5678 / 1460105_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 62% 63% 59% 63% 63% 68% 63% 62% 65% 69% 63% 63% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7967963
GSM967853U87-EV human glioblastoma xenograft - Control 23.6723962
GSM967854U87-EV human glioblastoma xenograft - Control 33.7751263
GSM967855U87-EV human glioblastoma xenograft - Control 43.4998759
GSM967856U87-EV human glioblastoma xenograft - Control 53.7095563
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8408763
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2232568
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.7507363
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.7278262
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.8792165
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2932669
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7313863
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7665263
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7594163